In the GenomeDataLab, we use statistical genomics and machine learning to study quality control that protects the integrity of information stored in the DNA and mRNA of the cell. We study how DNA repair and chromatin organization protect the human genome  from mutations, and how QC mechanisms operate on the transcriptome to prevent expression of mutated mRNAs

We perform large-scale bioinformatic studies of multi-omic data from human tumors (somatic mutations, and transcriptomes), human populations (germline variation) and metagenomes (incl. human microbiomes).

We study mechanisms for maintaining genome stability in human cells via statistical analyses of mutation patterns in cancer, which often result from deficient DNA repair [ 1 ].  Next, we are interested in how mRNA synthesis and turnover pathways shape genomes and transcriptomes in health and disease [ 2 ]. Finally, we combine experimental work and genomics to scan cancer genomes for drivers and genetic interactions to predict tumor evolution and identify novel synthetic lethalities [ 3 ].  More generally, we study novel approaches using artificial intelligence (AI) to infer DNA functionality from massive genomic data [ 4 ].

👉read more about our research interests >>>  

Some recent research 📜 from the GenomeDataLab:

Mas-Ponte & Supek (2024) Nucleic Acids Research

Meet the GenomeDataLab team:

more info on
team members:

👶students

🕺postdocs

🧛PI

See what we're up to on Twitter/X:
@genomeDataLab

GenomeDataLab ❤️ collaborations:

(w/ Ben Lehner lab, Sanger Institute/CRG)

(w/ RARAF facility at Columbia university)

(w/ Travis Stracker lab, currently at NIH)

(w/ Aznar lab at IRB Barcelona)

+ other great ongoing collaborations 🤝 

... interested in joint work?  Drop us a note (Fran's contact here)

We gratefully acknowledge our funders:

European Research Council ERC Consolidator Grant #101088342 STRUCTOMATIC "Mutational processes and impact of structural variants in somatic cells

CaixaResearch foundation "POTENT-IMMUNO" -Boosting immunotherapy by genomic prediction and NMD inhibitors.

EU H-2020 "DECIDER" Clinical Decision via Integrating Multiple Data Levels to Overcome Chemotherapy Resistance in High-Grade Serous Ovarian Cancer

Novo Nordisk Foundation Starting Package Grant 

We are further funded by the Horizon EU project "LUCIA" and the Danish Cancer Society.   More information on projects >>>

We are a part of the 🧱Biotech Research & Innovation Centre (BRIC) at University of Copenhagen; secondary affiliation of the lab is the 🏖️Institute for Research in Biomedicine (IRB Barcelona):

Other affiliations:

PI is tenured (on leave) via the ICREA Research Professor program of the Catalan government.

Fran Supek is a member of the EMBO Young Investigator programme.

"Prediction is very difficult, especially about the future." -- Niels Bohr.